Fauzi Asra Al, Thamrin Ahmad Muslim Hidayat, Permana Andhika Tomy, Ranuh I G M Aswin R, Hidayati Hanik Badriyah, Hamdan Muhammad, Wahyuhadi Joni, Suroto Nur Setiawan, Lestari Pudji, Chandra Poodipedi Sarat
Department of Neurosurgery, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia.
Department of Neurology, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia.
J Clin Med. 2023 Apr 6;12(7):2735. doi: 10.3390/jcm12072735.
Stem cell treatment is emerging as an appealing alternative for stroke patients, but there still needs to be an agreement on the protocols in place, including the route of administration. This systematic review aimed to assess the efficacy and safety of the administration routes of stem cell treatment for ischemic stroke. A systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. A comprehensive literature search was undertaken using the PubMed, Scopus, and Cochrane databases. A total of 21 publications on stem cell therapy for ischemic stroke were included. Efficacy outcomes were measured using the National Institutes of Health Stroke Scale (NIHSS), the modified Rankin Scale (mRS), and the Barthel index (BI). Intracerebral administration showed a better outcome than other routes, but a greater number of adverse events followed due to its invasiveness. Adverse events were shown to be related to the natural history of stroke not to the treatment. However, further investigation is required, since studies have yet to compare the different administration methods directly.
干细胞治疗正在成为中风患者一种有吸引力的替代疗法，但在包括给药途径在内的现有方案上仍需达成共识。本系统评价旨在评估干细胞治疗缺血性中风给药途径的疗效和安全性。根据系统评价和Meta分析的首选报告项目（PRISMA）指南进行了系统评价。使用PubMed、Scopus和Cochrane数据库进行了全面的文献检索。共纳入21篇关于缺血性中风干细胞治疗的出版物。疗效结果采用美国国立卫生研究院卒中量表（NIHSS）、改良Rankin量表（mRS）和Barthel指数（BI）进行测量。脑内给药显示出比其他途径更好的结果，但由于其侵入性，随后出现了更多的不良事件。不良事件被证明与中风的自然病程有关，而非与治疗有关。然而，由于研究尚未直接比较不同的给药方法，因此需要进一步研究。
